Navigation Links
Thalidomide shows efficacy as adjuvant therapy for hepatocellular carcinoma patients
Date:4/1/2011

Berlin, Germany, Saturday 02 April 2011: Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma (HCC), according to data presented at the International Liver CongressTM 2011.1

A new study found thalidomide gave HCC patients who'd undergone grossly curative resection surgical removal of the cancerous part of the liver double the two-year disease free survival rate (65%) compared to placebo (33%).

However, the study did find that the two-year overall survival rate was comparable between patients treated with thalidomide and patients given placebo 84.2% and 85.7% respectively.

Daniele Prati, EASL's Scientific Committee Member and Press Committee Chairman, commented: "Current options for adjuvant therapy in HCC are very limited and clinical trial results have been disappointing. Thalidomide has already been proven to work well in a number of other areas and this study shows it could potentially benefit HCC patients who are particularly difficult to treat. Overall, it is important to continue research in evaluating adjuvant therapy in HCC."

Surgery is the main form of treatment for HCC, but is only possible for a small proportion of those afflicted. Even after curative resection, recurrence is common and is the main cause of death. Adjuvant therapy that is, chemotherapy after surgery is thus attempted to try to improve outcomes.2

The study is promising because there is currently no adjuvant therapy for HCC patients following curative resection.

Indeed, the most up-to-date Cochrane Review of adjuvant therapies for HCC (conducted prior to this thalidomide study) found insufficient evidence to show that previously investigated adjuvant therapies increased survival for HCC, and only limited evidence to suggest that adjuvant therapy was useful in disease-free survival.2

In the double-blind, placebo controlled, randomized, comparative phase-II study, 42 patients were given 200mg per day oral dose of thalidomide (Arm A, 21 patients) or 200mg per day oral dose of placebo (Arm B, 21 patients). Patients started treatment within 6 weeks of complete tumor resection and carried on treatment for 12 months, or until they encountered disease recurrence, intolerably toxicity, or withdrew consent. Overall, thalidomide showed a good tolerability profile.

Thalidomide is currently approved by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) in the US for the treatment of multiple myeloma (a cancer of the bone marrow).3,4


'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-784-306-9451
European Association for the Study of the Liver
Source:Eurekalert

Related biology news :

1. Closer look at cell membrane shows cholesterol keeping order
2. New study shows you can have your candy and eat it too -- without adverse health effects
3. Study shows hunger hitting closer to home
4. GPS study shows wolves more reliant on a cattle diet
5. Russian boreal forests undergoing vegetation change, study shows
6. Research shows not only the fittest survive
7. Study shows living at high altitude reduces risk of dying from heart disease
8. UCSF team shows how to make skinny worms fat and fat worms skinny
9. Getting organized: Berkeley Lab study shows how breast cell communities organize into breast tissue
10. Finding shows potential way to protect neurons in Parkinsons, Alzheimers, ALS
11. Study shows new treatment strategy effective for certain lung cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. ... Used combined in one project, multi-biometric solutions ... ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... ... April 20, 2017 , ... ... scientific and clinical research community’s growing body of knowledge during its Eighth ... Gracie Theatre and the adjacent Darling Atrium. During the event, undergraduates, graduate students, ...
(Date:4/20/2017)... , April 20, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: ... results at the International Liver Congress ("ILC") 2017 of the ... Amsterdam on the positive effects of ... model of obesity and metabolic syndrome. ... According to Dr. Lyne Gagnon, Vice-President of R&D ...
(Date:4/20/2017)... ... April 20, 2017 , ... Parallel6™ , the leader in ... today that they were named one of the 2017 Top 10 eClinical Trial ... in the pharmaceutical industry. , “We take pride in honoring Parallel6 as one of ...
(Date:4/20/2017)... Dutch philosopher Koert van Mensvoort - founder of the Next Nature Network ... - has written a ,Letter to Humanity, in support of International ... a slave and victim to its own technology, but to employ technology to ... ... – founder of the Next Nature Network and Fellow of ‘Next Nature’ at ...
Breaking Biology Technology: